CLINICAL THYROIDOLOGY FOR THE PUBLIC
A publication of the American Thyroid Association

Table of Contents

EDITOR’S COMMENTS

Welcome to another issue of Clinical Thyroidology for the Public. In this journal, we will bring to you the most up-to-date, cutting edge thyroid research. We will be providing summaries of research studies that were discussed in a recent issue of Clinical Thyroidology, a publication of the American Thyroid Association for physicians. These summaries are presented in lay language to allow the rapid dissemination of thyroid research to the widest possible audience. This means that you are getting the latest information on thyroid research and treatment almost as soon as your physicians. As always, we are happy to entertain any suggestions to improve Clinical Thyroidology for the Public so let us know what you want to see.

We also provide even faster updates of late-breaking thyroid news through Twitter at @thyroidfriends and on Facebook. Our goal is to provide patients with the tools to be the most informed thyroid patient in the waiting room.

Also check out our friends in the ATA Alliance for Thyroid Patient Education. The Alliance member groups consist of: the American Thyroid Association, the Graves’ Disease and Thyroid Foundation, the Light of Life Foundation, ThyCa: Thyroid Cancer Survivors Association, Thyroid Cancer Canada and Thyroid Federation International.

November is Hyperthyroidism Awareness Month.

In this issue, the studies ask the following questions:

  1. Should infertile women with subclinical hypothyroidism be treated?
  2. Do ultrasound features of cancerous thyroid nodules predict thyroid cancer recurrence?
  3. How well does the Afirma gene expression classifier predict cancer in patients with indeterminate hurtle cell biopsies?
  4. How effective is Levatinib in treating patients with metastatic medullary thyroid cancer?
  5. Does molecular marker analysis of thyroid cancer biopsies correlate with recurrent or persistent cancer?

We welcome your feedback and suggestions. Let us know what you want to see in this publication. I hope you find these summaries interesting and informative.

— Alan P. Farwell, MD, FACE